<DOC>
	<DOCNO>NCT01214278</DOCNO>
	<brief_summary>The aim study examine difference short term bioavailability four n-3 FA formulation healthy male .</brief_summary>
	<brief_title>Bioavailability Different n-3 Fatty Acid Formulations</brief_title>
	<detailed_description>The long-chain n-3 fatty acid ( n-3 FAs ) eicosapentaenoic acid ( EPA ) docosahexaenoic acid ( DHA ) know positively affect lipid profile , vascular tone blood coagulation . Moreover , EPA DHA possess anti-inflammatory effect play central role function brain central nervous system . Therefore , increase EPA DHA intake highly recommend . However , unknown whether different chemical formulation EPA + DHA rich supplement ( re-esterified triglyceride , ethyl-esters , phospholipid ) identical bioavailability . The objective study examine difference short term bioavailability four n-3 FA formulation : - Supplement 1 : EPA+DHA re-esterified triglyceride ( rTGs ) fish-oil uncoated capsule - Supplement 2 : EPA+DHA rTGs fish-oil gastric acid resistant ( coat ) capsule ( GArTG ) - Supplement 3 : EPA+DHA ethylesters ( EE ) fish-oil uncoated capsule - Supplement 4 : DHA+EPA phospholipid krill-oil , uncoated capsule ( KPL ) The study preparation certificate supplement available market . There comparative investigation , analyze bioavailability four n-3 FA formulation similar design .</detailed_description>
	<criteria>male , 2050 year , Caucasian , healthy , body mass index ( BMI ) 2028 kg/mÂ² , medical treatment , write confirmation subject detail spoken write explanation study content , ability willingness participant attend investigator 's order ( compliance study condition , consumption study drug accord dosage commendation medical treatment ( especially corticosteroid , antiinflammatory drug , blood lipid lower drug ( e.g . statines , fibrates , bile acid exchanger resin , phytosterols ) take supplement n3 FAs , phytosterols , polyglucosamines ( Chitosan ) lipid bind ingredient daily consumption n3 FAs rich fish ( salmon , mackerel , herring ) heavy chronic disease ( tumor , diabetes typ 1 , etc . ) , documented heart disease , document blood clotting disorder , renal failure , liver disease document blood clot disorder consumption coagulationinhibiting drug ( example Marcumar , ASS ) allergy intolerance fish/fish oil study ingredient test product chronic gastrointestinal disease ( Colitis ulcerosa , Morbus Crohn , pancreatic insufficiency ) donation blood last 6 week routine consumption laxative alcohol , drug and/or medicament dependence subject agreement study condition refusal rather reset consent subject active participation investigational drug device trial within last 30 day</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>bioavailability</keyword>
	<keyword>marine n-3 fatty acid</keyword>
	<keyword>EPA</keyword>
	<keyword>DHA</keyword>
</DOC>